![抗体靶向治疗药物_第1页](http://file.renrendoc.com/FileRoot1/2017-12/7/af051425-1969-40bb-a4b5-24b5b83de734/af051425-1969-40bb-a4b5-24b5b83de7341.gif)
![抗体靶向治疗药物_第2页](http://file.renrendoc.com/FileRoot1/2017-12/7/af051425-1969-40bb-a4b5-24b5b83de734/af051425-1969-40bb-a4b5-24b5b83de7342.gif)
![抗体靶向治疗药物_第3页](http://file.renrendoc.com/FileRoot1/2017-12/7/af051425-1969-40bb-a4b5-24b5b83de734/af051425-1969-40bb-a4b5-24b5b83de7343.gif)
![抗体靶向治疗药物_第4页](http://file.renrendoc.com/FileRoot1/2017-12/7/af051425-1969-40bb-a4b5-24b5b83de734/af051425-1969-40bb-a4b5-24b5b83de7344.gif)
![抗体靶向治疗药物_第5页](http://file.renrendoc.com/FileRoot1/2017-12/7/af051425-1969-40bb-a4b5-24b5b83de734/af051425-1969-40bb-a4b5-24b5b83de7345.gif)
已阅读5页,还剩45页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
抗体靶向治疗药物,邵荣光,甄永苏: 抗体靶向治疗药物 见:王晓良主编. 应用分子药理学. 中国协和医科大学出版社,北京,2005,甄永苏,邵荣光主编: 抗体工程药物 化学工业出版社,北京,2002,B淋巴细胞杂交瘤技术,Mechanism of Action: Monoclonal Ab,Malignantcell,Monoclonal Ab,Tumor specific Ag,Complement,Killerleukocyte,ADCC(Ab dependent cell-mediated cytotoxicity),CDC(Complement dependent cytotoxicity),Monoclonal Ab,Ligand dependent apoptosis,Graphic representation of progression of monoclonal antibodies from murine to chimeric to humanized to PRIMATIZED and human. The more human the antibody is, the less likely it will generate an immune response and the more utility it has for chronic (repeat) therapy.,Generations of antibody technology,与单抗偶联的常用“弹头”药物,毒素植物 蓖麻毒素,相思豆毒素,saporin,gelonin,modecin等微生物 绿脓杆菌外毒素,白喉毒素 药物抗代谢类 氨基蝶呤,MTX,Ara-C,5-FU,5-氟脱氧尿苷等蒽环类 阿霉素,柔红霉素,去甲氧柔红霉素,吗啉阿霉素等烷基化类 苯丙氨酸氮芥,苯丁酸氮芥,丝裂霉素C,顺铂等抗有丝分裂 长春花碱,秋水仙碱,鬼臼毒素等抗生素 Calicheamicin,博莱霉素,平阳霉素,力达霉素 核素 131I、125I、90Y 、67Cu 、111In 、99mTc等,Physical characteristics of some therapeutic radionuclides,碘砹铋镧铜,Monoclonal antibodies in the order of FDA-approval,FDA: 35 SFDA: 11 15BUS 1/3 BIO,US and EU therapeutic mAb approvals to date,1, chimeric mAbs, all products (n = 39); 2, oncological chimeric mAbs (n = 21); 3, immunological chimeric mAbs (n = 9); 4, chimeric mAbs, 19871997 (n = 20); 5, humanized mAbs, all products (n = 102); 6, oncological humanized mAbs (n = 46); 7, immunological humanized mAbs (n = 34); 8, humanized mAbs, 19881997 (n = 46).,Data are presented as two-year moving averages,Number of therapeutic mAbs entering clinical study per year,Clinical phase transition percentages for therapeutic mAbs (FDA data),Approval success rates for mAbs,Misc., miscellaneous categoryincluding ophthalmic, neuropharmacologic and cardiovascular indications.,Therapeutic categories for mAbs in clinical study,影响抗体治疗的主要障碍1. 异源抗体的免疫原性 (Immunogenicity of xenogeneic antibodies)2. 抗原脱落进入血循环 (Shedding of antigen into circulation)3. 肿瘤内血管的失调 (Disordered vasculature in tumors)4. 肿瘤内静水压的增加 (Increased hydrostatic pressure in tumors)5. 肿瘤表面抗原的异质性 (Heterogeneity of antigen on tumor surface)6. 肿瘤效应细胞数量的限制 (Limited numbers of effector cells at tumor)7. 免疫抑制性肿瘤微环境 (Immunosuppressive tumor microenvironment),Serial microPET imaging of 124I-labeled anti-CEA scFv-Fc fragments Parental human 1 and H310A/H435Q double mutant in LS174T xenograft-bearing mice. The image marked scFv-Fc SM is a H310A single mutant of the mAb; scFv-Fc DM is a H310A/H435Q double mutant.,Relationship between engineered antibody format, targeting and imaging, and blood clearance,Schematic showing domain composition of engineered fragments,(25 kDa) (55 kDa) (80 kDa) (105 kDa) (150 kDa),Tumor uptake and blood clearance curves For radioiodine-labeled anti-CEA scFv mAb fragments in athymic mice bearing subcutaneous LS174T human colon carcinoma xenografts. ID/g: injected dose per gram.,Biodistribution of different mAb formats in two xenograft models,A cartoon representation of different antibody formats used for in vivo imaging,MicroPET scan of athymic mice with LS174T colon carcinoma (left arrow) and C6 glioma (right arrow) tumors 18 h post infusion of 124I-labeled anti-CEA T84.66 diabody, minibody or scFv-Fc,Antibody formats used in imaging,Camelid VhH-Ig and shark Ig-NARs are unusual immunoglobulin-like structures comprising a homodimeric pair of two chains of V-like and C-like domains (neither has a light chain), in which the displayed V domains bind target independently. Shark Ig-NARs comprise a homodimer of one variable domain (V-NAR) and five C-like constant domains (C-NAR). A variety of antibody fragments are depicted, including Fab, scFv, single-domain VH, VhH and V-NAR and multimeric formats, such as minibodies, bis-scFv, diabodies, triabodies, tetrabodies and chemically conjugated Fab multimers (sizes given in kilodaltons are approximate).,Schematic representation of different antibody formats, showing intact classic IgG molecules alongside camelid VhH-Ig and shark Ig-NAR immunoglobulins,Structural comparison of antibody fragments and single domains,FDA 批准用于治疗肿瘤的抗体药物,Rituxan (1997):非霍奇金B 细胞淋巴瘤Herceptin (1998):乳腺癌Mylotarg (2000):复发的急性髓细胞性白血病Campath-1H (2001):难治的慢性淋巴细胞白血病Zevalin (2002):难治的非霍奇金B 细胞淋巴瘤Bexxar (2003):难治的非霍奇金B 细胞淋巴瘤Erbitux (2004):结肠直肠癌Avastin (2004):结肠直肠癌Vectibix (2006):结肠直肠癌,单克隆抗体肿瘤靶向治疗 bind to antigens present preferentially or exclusively on tumor cells.,ZevalinBexxar,Mylotarg,单克隆抗体作为肿瘤治疗的体内应用策略,Antibody Alone Complement mediated cytotoxicity (CMC) Antibody dependent cell-mediated cytotoxicity (ADCC) Regulatory (ligand/receptor) interactions Anti-idiotype vaccineImmunoconjugates Radiolabeled Antibodies Immunotoxins Chemotherapy-Antibody Conjugates Cytokine Immunoconjugates Cellular Immunoconjugates,Antibody fragments in clinical and preclinical development,Antibody fragments in clinical and preclinical development,Therapeutic mAbs currently in phase 3 studies,CTLA, cytotoxic T-lymphocyte associated protein; EGF, epidermal growth factor; MRSA, methicillin-resistant Staphylococcus aureus; RANKL, receptor for activation of nuclear factor-B ligand; RSV, respiratory syncytial virus; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.,近几年处在临床实验中的免疫毒素,AAPS J 2006,近几年处在临床实验中的免疫毒素,AAPS J 2006,Thanks You!,Schematic representation of immunoglobulin fragments,Fab,scFv,diabody,dAb (VH or VL),Possible different configurations of fusion proteins of cytokines with either full-length antibody molecules or the antigen-binding sites (scFv) are depicted. The cy
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 次六年级上数学 导学案
- 银行系统招聘考试英语(中国农业银行)模拟试卷3
- 痛风的表现诊断及预防
- 《财经新闻信息+第2部分:传输处理接口要求gbt+43340.2-2023》详细解读
- 英语作文我的家规和朋友的家规七年级
- 数说故事-《AI+KOX数智化运营》N次方全域营销裂变解决方案
- 幼儿园小班科学课件:《快餐店》
- 2022年度辽宁省安全员之C2证(土建安全员)练习题(五)及答案
- 2022年度辽宁省安全员之C1证(机械安全员)强化训练试卷A卷附答案
- 万丽酒店成本控制管理研究
- 小学三年级奥数面积计算(共2页)
- 小学语文作文教学研究课题调查问卷
- 苏教版科学三年级上《把盐放到水里》教学案例
- 人教版九年级上册数学教案 23.1 图形的旋转
- 成品入库登记表
- 规模以上工业法人单位科技活动及相关情况607-2
- 浅谈建设工程质量安全监督中存在的问题和建议
- 药物化学抗肿瘤药烷化剂氮芥类
- 测绘成果检查验收报告
- 2021年全国高中数学联赛广东省赛区预赛试题及答案
- 应急逃生与急救安全知识课件PPT
评论
0/150
提交评论